{"id":"W4296529229","doi":"10.1016/s2152-2650(22)01498-7","title":"ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada); Sunnybrook Health Science Centre; Health Sciences Centre; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Rituximab; Vincristine; Internal medicine; Prednisone; Gastroenterology; CHOP; Hazard ratio; Cyclophosphamide; Clinical endpoint; International Prognostic Index; Surgery; Confidence interval; Lymphoma; Chemotherapy; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001514116,0.0008275502,0.001346053,0.0003240692,0.0002008762,0.00123647,0.0007315641,0.0007123164,0.002639616],"category_scores_gemma":[0.0007629298,0.0003757686,0.001037352,0.0004394926,0.0009102251,0.0008754815,0.0003394898,0.002223814,0.0006173498],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001196045,"about_ca_system_score_gemma":0.001059182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001826628,"about_ca_topic_score_gemma":0.003699837,"domain_scores_codex":[0.9995277,0.0002609074,0.00001807167,0.00006756759,0.00004002453,0.00008568087],"domain_scores_gemma":[0.9994236,0.0001745669,0.0001058097,0.00003507998,0.00002349918,0.0002375439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8803734,0.01198333,0.006567828,0.0003624881,0.001607167,0.0000903651,0.0001435751,0.002573411,0.01295529,0.0003318401,0.0021966,0.0808147],"study_design_scores_gemma":[0.6591365,0.2991146,0.03064457,0.00006624145,0.001630421,0.0002867596,0.0001485203,0.002461149,0.002637299,0.0003421256,0.003491495,0.00004027749],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943309,0.002727726,0.0001737704,0.0003820094,0.00009842282,0.0001860493,0.0005124962,0.00004573626,0.001542862],"genre_scores_gemma":[0.9943354,0.001738964,0.0003569613,0.0004810297,0.0001215409,0.0001741249,0.001328088,0.00001915809,0.00144487],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002639616,"threshold_uncertainty_score":0.008830428,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0161700712894621,"score_gpt":0.2827769139615351,"score_spread":0.266606842672073,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}